Bettiol, Alessandra
Marconi, Ettore
Vannacci, Alfredo
Simonetti, Monica
Magni, Alberto
Cricelli, Claudio
Lapi, Francesco http://orcid.org/0000-0002-4342-9128
Funding for this research was provided by:
Angelini Pharma
Article History
Received: 3 October 2019
Accepted: 8 December 2020
First Online: 7 January 2021
Conflicts of interest
: Lapi and Marconi provided consultancies in protocol preparation for epidemiological studies and data analyses for IBSA, Bayer AlfaSigma and Angelini. Cricelli provided clinical consultancies for IBSA, Angelini, Grunenthal, AlfaSigma, Pfizer, Prostrakan, Molteni, Dompè and Teva. Magni provided clinical consultancies for Bayer, Angelini, Doc, and AlfaSigma. Authors Bettiol, Simonetti and Vannacci have no conflicts of interest to disclose.